278 related articles for article (PubMed ID: 21975930)
1. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer.
Patel V; Marsh CA; Dorsam RT; Mikelis CM; Masedunskas A; Amornphimoltham P; Nathan CA; Singh B; Weigert R; Molinolo AA; Gutkind JS
Cancer Res; 2011 Nov; 71(22):7103-12. PubMed ID: 21975930
[TBL] [Abstract][Full Text] [Related]
2. Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models.
Ekshyyan O; Moore-Medlin TN; Raley MC; Sonavane K; Rong X; Brodt MA; Abreo F; Alexander JS; Nathan CA
BMC Cancer; 2013 Jul; 13():320. PubMed ID: 23815869
[TBL] [Abstract][Full Text] [Related]
3. Genetic Identification of SEMA3F as an Antilymphangiogenic Metastasis Suppressor Gene in Head and Neck Squamous Carcinoma.
Doçi CL; Mikelis CM; Lionakis MS; Molinolo AA; Gutkind JS
Cancer Res; 2015 Jul; 75(14):2937-48. PubMed ID: 25952650
[TBL] [Abstract][Full Text] [Related]
4. mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.
Molinolo AA; Marsh C; El Dinali M; Gangane N; Jennison K; Hewitt S; Patel V; Seiwert TY; Gutkind JS
Clin Cancer Res; 2012 May; 18(9):2558-68. PubMed ID: 22409888
[TBL] [Abstract][Full Text] [Related]
5. mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.
Coppock JD; Vermeer PD; Vermeer DW; Lee KM; Miskimins WK; Spanos WC; Lee JH
Oncotarget; 2016 Apr; 7(17):24228-41. PubMed ID: 27015118
[TBL] [Abstract][Full Text] [Related]
6. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
[TBL] [Abstract][Full Text] [Related]
7. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
[TBL] [Abstract][Full Text] [Related]
8. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.
Amornphimoltham P; Patel V; Leelahavanichkul K; Abraham RT; Gutkind JS
Cancer Res; 2008 Feb; 68(4):1144-53. PubMed ID: 18281490
[TBL] [Abstract][Full Text] [Related]
9. mTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma.
Nguyen SA; Walker D; Gillespie MB; Gutkind JS; Day TA
Curr Treat Options Oncol; 2012 Mar; 13(1):71-81. PubMed ID: 22282394
[TBL] [Abstract][Full Text] [Related]
10. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
11. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model.
Czerninski R; Amornphimoltham P; Patel V; Molinolo AA; Gutkind JS
Cancer Prev Res (Phila); 2009 Jan; 2(1):27-36. PubMed ID: 19139015
[TBL] [Abstract][Full Text] [Related]
12. A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option.
Klinghammer K; Raguse JD; Plath T; Albers AE; Joehrens K; Zakarneh A; Brzezicha B; Wulf-Goldenberg A; Keilholz U; Hoffmann J; Fichtner I
Int J Cancer; 2015 Jun; 136(12):2940-8. PubMed ID: 25404014
[TBL] [Abstract][Full Text] [Related]
13. Inducible nitric oxide synthase activity correlates with lymphangiogenesis and vascular endothelial growth factor-C expression in head and neck squamous cell carcinoma.
Franchi A; Massi D; Santucci M; Masini E; Rossi Degl'Innocenti D; Magnelli L; Fanti E; Naldini A; Ardinghi C; Carraro F; Gallo O
J Pathol; 2006 Feb; 208(3):439-45. PubMed ID: 16278821
[TBL] [Abstract][Full Text] [Related]
14. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
Coppock JD; Wieking BG; Molinolo AA; Gutkind JS; Miskimins WK; Lee JH
Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
[TBL] [Abstract][Full Text] [Related]
15. Tumor lymphangiogenesis in head and neck squamous cell carcinoma: a morphometric study with clinical correlations.
Franchi A; Gallo O; Massi D; Baroni G; Santucci M
Cancer; 2004 Sep; 101(5):973-8. PubMed ID: 15329906
[TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer.
Nathan CO; Amirghahari N; Rong X; Giordano T; Sibley D; Nordberg M; Glass J; Agarwal A; Caldito G
Cancer Res; 2007 Mar; 67(5):2160-8. PubMed ID: 17332346
[TBL] [Abstract][Full Text] [Related]
17. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
Xie J; Li Q; Ding X; Gao Y
Cell Physiol Biochem; 2018; 46(2):676-686. PubMed ID: 29621758
[TBL] [Abstract][Full Text] [Related]
18. 3-O-Acetyloleanolic acid inhibits VEGF-A-induced lymphangiogenesis and lymph node metastasis in an oral cancer sentinel lymph node animal model.
Hwang-Bo J; Bae MG; Park JH; Chung IS
BMC Cancer; 2018 Jul; 18(1):714. PubMed ID: 29976150
[TBL] [Abstract][Full Text] [Related]
19. Autophagy induction contributes to GDC-0349 resistance in head and neck squamous cell carcinoma (HNSCC) cells.
Zhou Y; Peng Y; Tang H; He X; Wang Z; Hu D; Zhou X
Biochem Biophys Res Commun; 2016 Aug; 477(2):174-80. PubMed ID: 27291151
[TBL] [Abstract][Full Text] [Related]
20. Head and neck squamous cell carcinoma lymphatic spread and survival: Relevance of vascular endothelial growth factor family for tumor evaluation.
de Sousa EA; Lourenço SV; de Moraes FP; Vartanian JG; Gonçalves-Filho J; Kowalski LP; Soares FA; Coutinho-Camillo CM
Head Neck; 2015 Oct; 37(10):1410-6. PubMed ID: 24824527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
